TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02772783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high GI meal
Description: High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of \~90 is achieved by using corn syrup as a carbohydrate source.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high GI meal
Description: High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of \~90 is achieved by using corn syrup as a carbohydrate source.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low GI meal
Description: High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A low glycemic index of \~40 is achieved by using uncooked corn starch as a carbohydrate source.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: euglycemic insulin clamp
Description: Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: euglycemic insulin clamp
Description: Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primed-variable insulin infusion
Description: A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are \> 400 mg/dl or \< 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
Study: NCT04026789

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Same-day-start
Description: Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delay-for-diagnosis
Description: Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
Study: NCT01374698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 325 mg
Study: NCT03246074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg bid and Paclitaxel
Description: Drug: Fostamatinib (oral; 100 mg bid)~Drug: Paclitaxel (60-80 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib 150 mg bid and Paclitaxel
Description: Drug: Fostamatinib (oral; 150 mg bid)~Drug: Paclitaxel (60-80 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib 200 mg bid and Paclitaxel
Description: Drug: Fostamatinib (oral; 200 mg bid)~Drug: Paclitaxel (60-80 mg/m2)
Study: NCT04444050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986331
Description: Specified dose on specified days
Study: NCT00956189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amisulpride
Description: Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
Study: NCT00777842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GTX™ Drug Eluting Coronary Stent System
Description: Drug eluting stent
Study: NCT03763981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prolene seton treatment
Description: patients with perianal fistulas will treated with seton placement by prolene thread

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: silk seton treatment
Description: patients with perianal fistulas will treated with seton placement by silk thread
Study: NCT03243019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: oral administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: cervicofacial MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rapamycin dosage
Description: Biological dosage of Rapamycin level
Study: NCT03677401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg Serlopitant Tablets
Description: Serlopitant Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo Tablets
Study: NCT02711787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Robotic assisted passive mobilization (Gloreha, Idrogenet, Italy) and traditional rehabilitation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Physiotherapy and occupational therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation
Description: Assisted stretching, shoulder and arm exercises, and functional reaching tasks
Study: NCT01053910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: tablet of Ramipril once daily
Study: NCT02711787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional rehabilitation
Description: Assisted stretching, shoulder and arm exercises, and functional reaching tasks
Study: NCT01500083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine at a dose of 100 mg/m2
Description: Bendamustine will be administered intravenously over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine at a dose of 120 mg/m2
Description: Bendamustine will be administered intravenous (i.v.) over 60 minutes.
Study: NCT04664114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Ultrasound images of the fetus in the 28th week of pregnancy of the women in the intervention group were recorded. These images were shown to the woman through virtual reality glasses during the labor. Routine practices in the hospital were made to the women in the control group. VAS (Visual Analog Scale) was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale (POBS) and Perinatal Anxiety Screening Scale (PASS) were administered.
Study: NCT01562444

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: Annual blood draw at years 6 (Visit 18), 7 (Visit 19), 8 (Visit 20), 9 (Visit 21) and 10 (Visit 22)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: Annual blood draw at years 6 (Visit 18), 7 (Visit 19), 8 (Visit 20), 9 (Visit 21) and 10 (Visit 22)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: Annual blood draw at years 6 (Visit 18), 7 (Visit 19), 8 (Visit 20), 9 (Visit 21) and 10 (Visit 22)
Study: NCT04491487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre-operative counselling
Description: pre-operative Speech-Language Pathology (SLP) counselling before Total Laryngectomy
Study: NCT01926535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant of amniotic membrane grafts
Description: Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic contact lenses
Description: Therapeutic contact lenses were applied in all patients included in the control group and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
Study: NCT01177410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine Granules 750 mg
Description: 750 mg mesalamine granules once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine Granules 1500 mg
Description: 1500 mg mesalamine granules once daily for 12 weeks
Study: NCT03779607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Celtra Press
Description: new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Celtra Press
Description: new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing.
Study: NCT01025050

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrastromal Correction of Presbyopia
Description: On all patients an intrastromal pattern consisting of concentric rings will be applied.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrastromal Correction of Presbyopia
Description: On all patients an intrastromal pattern consisting of concentric rings will be applied.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrastromal Correction of Presbyopia
Description: On all patients an intrastromal pattern consisting of concentric rings will be applied.
Study: NCT02200081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other
Study: NCT03791931

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: oxidative stress measurement
Description: oxidative stress measurement
Study: NCT02955693

Intervention type: DRUG
Group type: OTHER
Intervention: LAS41008 120 mg / Fumaderm® 120 mg
Description: Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period

Intervention type: DRUG
Group type: OTHER
Intervention: LAS41008 120 mg / Fumaderm® 120 mg
Description: Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
Study: NCT01201499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: a single dose of intrathecal morphine (ITM, 4 µcg/kg, or \~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous IV remifentanil
Description: a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
Study: NCT03146364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality - Virtual Interactive Supermarket
Description: SeeMe is a PC based, innovative, comprehensive, clinician-controlled exercise and diagnostic system. SeeMe is designed to aid the rehabilitation process, and track patients' progress.~Virtual Interactive Supermarket- one of the SeeMe Tasks, the user need to buy products by according to specific instruction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality - Virtual Interactive Supermarket
Description: SeeMe is a PC based, innovative, comprehensive, clinician-controlled exercise and diagnostic system. SeeMe is designed to aid the rehabilitation process, and track patients' progress.~Virtual Interactive Supermarket- one of the SeeMe Tasks, the user need to buy products by according to specific instruction
Study: NCT00979511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk and exercise
Description: * milk fortified with 1000mg calcium or low-calcium milk~* weight-bearing exercise or passive exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk and exercise
Description: * milk fortified with 1000mg calcium or low-calcium milk~* weight-bearing exercise or passive exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk and exercise
Description: * milk fortified with 1000mg calcium or low-calcium milk~* weight-bearing exercise or passive exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk and exercise
Description: * milk fortified with 1000mg calcium or low-calcium milk~* weight-bearing exercise or passive exercise
Study: NCT00609505

Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine
Description: Telemedicine genetic counseling

Intervention type: OTHER
Group type: OTHER
Intervention: Face-to-Face
Description: Face-to-face genetic counseling
Study: NCT00248547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone
Description: For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ondansetron
Description: For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
Study: NCT03590860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3322207
Description: Administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3322207
Description: Administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3322207
Description: Administered by SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by SC injection
Study: NCT04615507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lens
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lens
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lens
Description: CONTROL Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lens
Description: CONTROL Lens
Study: NCT03494179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: The drug product is a white, round, uncoated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: The drug product is a white, round, uncoated tablet.
Study: NCT02992379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pivot splint
Description: A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of selfcuring acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pivot splint
Description: A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of selfcuring acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stabilizing splint
Description: A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stabilizing splint
Description: A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
Study: NCT02852044

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rest
Description: Allowed to watch television or read for one hour prior to oral glucose tolerance test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: One hour of cycling at 50% of maximal power output

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dorsal Hand Vein Cannulation (heated hand technique)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Hand Vein Cannulation (heated hand technique)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous Cannulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Venous Cannulation